At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 108 enrolled
Drug / intervention
rizatriptan benzoate +1 moredrug
Likely dose
rizatriptan benzoate 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
In Brief
A Phase 3 clinical trial evaluating rizatriptan benzoate and Comparator: placebo for Migraine. Completed, enrolled 108 participants.
Detailed Summary
This study will provide additional efficacy data for rizatriptan when used for an acute migraine attack in patients already taking topiramate for migraine prophylaxis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartMar 2009
Primary CompletionOct 2009
TodayJul 2026
First PostedDec 19, 2008
Enrollment StartMar 24, 2009
Primary CompletionOct 22, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.5 years ago
Interventions
rizatriptan benzoatedrug
rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
Comparator: placebodrug
Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack